{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:59:22Z","timestamp":1793581162697,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL147835"],"award-info":[{"award-number":["P01HL147835"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK106419"],"award-info":[{"award-number":["R01DK106419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK121378"],"award-info":[{"award-number":["R01DK121378"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124318"],"award-info":[{"award-number":["R01DK124318"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK061734"],"award-info":[{"award-number":["U01DK061734"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK130190"],"award-info":[{"award-number":["U01DK130190"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001442"],"award-info":[{"award-number":["5UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3UL1TR004419"],"award-info":[{"award-number":["3UL1TR004419"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30CA196521"],"award-info":[{"award-number":["5P30CA196521"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK 121154-01A1"],"award-info":[{"award-number":["R01 DK 121154-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK128289"],"award-info":[{"award-number":["R01 DK128289"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01AA029019"],"award-info":[{"award-number":["U01AA029019"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jhep.2023.03.038","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:26:44Z","timestamp":1681446404000},"page":"552-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":326,"title":["An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2662-6127","authenticated-orcid":false,"given":"Tobias","family":"Puengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-6195","authenticated-orcid":false,"given":"Scott L.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2023.03.038_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"7","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.038_bib3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.03.038_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.038_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data","volume":"51","author":"Loomba","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.03.038_bib11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-1877-9656","article-title":"Nonalcoholic steatohepatitis drug development pipeline: an update","volume":"42","author":"Chew","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.03.038_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A\u00a0structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","author":"Fraser","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0042-1755316","article-title":"Metabolic injury of hepatocytes promotes progression of NAFLD and AALD","volume":"42","author":"Carvalho-Gontijo","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.03.038_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020652","article-title":"The potential role of cellular senescence in non-alcoholic fatty liver disease","volume":"23","author":"Engelmann","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.03.038_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41575-020-00365-6","article-title":"Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.03.038_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17446651.2022.2110864","article-title":"Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis","volume":"17","author":"Wirth","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.03.038_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib23","article-title":"Understanding the cellular interactome of non-alcoholic fatty liver disease","volume":"4","author":"Wallace","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib24","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Trepo","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jhep.2023.03.038_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.03.038_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep4.1395","article-title":"PNPLA3 I148M variant impairs liver X receptor signaling and cholesterol homeostasis in human hepatic stellate cells","volume":"3","author":"Bruschi","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.03.038_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.038_bib31","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.03.038_bib32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A\u00a0genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2023.03.038_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.03.038_bib35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cel Metab"},{"key":"10.1016\/j.jhep.2023.03.038_bib36","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","article-title":"Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease","volume":"158","author":"Azzu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2021.02.037","article-title":"Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity","volume":"75","author":"Nachit","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib38","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3389\/fimmu.2018.02418","article-title":"Adapted immune responses of myeloid-derived cells in fatty liver disease","volume":"9","author":"Hundertmark","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver--from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00281-021-00869-6","article-title":"Role of bile acids in inflammatory liver diseases","volume":"43","author":"Evangelakos","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2023.03.038_bib41","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.31523","article-title":"The commensal microbe veillonella as a marker for response to an FGF19 analog in NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.03.038_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.03.038_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14728222.2022.2132145","article-title":"Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease","volume":"26","author":"Laursen","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jhep.2023.03.038_bib48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000270","article-title":"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression","author":"Guillot","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41575-020-0304-x","article-title":"Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis","volume":"17","author":"Ramachandran","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib56","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A\u00a0subset of Kupffer cells regulates metabolism through the expression of CD36","volume":"54","author":"Bleriot","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2023.03.038_bib57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2023.03.038_bib58","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2023.03.038_bib59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2023.03.038_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/gutjnl-2019-318382","article-title":"Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis","volume":"69","author":"Krenkel","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.038_bib62","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.03.038_bib63","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1172\/JCI28898","article-title":"TLR4 links innate immunity and fatty acid-induced insulin resistance","volume":"116","author":"Shi","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.03.038_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0040-1708540","article-title":"The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis","volume":"40","author":"Knorr","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.03.038_bib65","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2023.03.038_bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib67","article-title":"The medium-chain fatty acid receptor GPR84 mediates myeloid cell infiltration promoting steatohepatitis and fibrosis","volume":"9","author":"Puengel","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib69","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib70","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jhep.2021.02.012","article-title":"Targeting cell-intrinsic metabolism for antifibrotic therapy","volume":"74","author":"Gilgenkrantz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib71","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib73","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.26783","article-title":"Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice","volume":"59","author":"Baeck","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib74","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib75","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.03.038_bib76","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0037-1604480","article-title":"Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism","volume":"37","author":"Krenkel","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.03.038_bib77","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib78","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib79","first-page":"256","article-title":"Treating inflammation to combat non-alcoholic fatty liver disease","author":"Wiering","year":"2023","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jhep.2023.03.038_bib80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm.4294","article-title":"An emerging role for neutrophil extracellular traps in noninfectious disease","volume":"23","author":"Jorch","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib82","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jhep.2013.12.005","article-title":"A\u00a0TLR2\/S100A9\/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse","volume":"60","author":"Moles","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/hep.31680","article-title":"Two faces of neutrophils in liver disease development and progression","volume":"74","author":"Cho","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib84","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41575-021-00568-5","article-title":"Neutrophils as potential therapeutic targets in hepatocellular carcinoma","volume":"19","author":"Geh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib85","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","article-title":"XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis","volume":"27","author":"Deczkowska","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2023.03.038_bib87","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib89","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/hep.31889","article-title":"The emerging role of B cells in the pathogenesis of NAFLD","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib90","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 Years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2023.03.038_bib91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/gutjnl-2011-301400","article-title":"NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis","volume":"61","author":"Gur","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.038_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640869","article-title":"Revisiting the role of natural killer cells in non-alcoholic fatty liver disease","volume":"12","author":"Martinez-Chantar","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib93","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.immuni.2016.06.016","article-title":"Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance","volume":"45","author":"O'Sullivan","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2023.03.038_bib94","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature14115","article-title":"Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity","volume":"519","author":"Brestoff","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib95","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41577-020-0345-y","article-title":"Thymic development of unconventional T cells: how NKT cells, MAIT cells and gammadelta T cells emerge","volume":"20","author":"Pellicci","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib96","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2011-301857","article-title":"NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease","volume":"61","author":"Syn","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.038_bib97","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.4049\/jimmunol.1202909","article-title":"Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis","volume":"190","author":"Wehr","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib99","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-018-04450-y","article-title":"Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver","volume":"9","author":"Hegde","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.03.038_bib100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep.29782","article-title":"MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation","volume":"68","author":"Bottcher","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib101","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib102","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Al Attar","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jhep.2023.03.038_bib103","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib104","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib106","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib107","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib108","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib109","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.celrep.2019.10.024","article-title":"Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis","volume":"29","author":"Dobie","year":"2019","journal-title":"Cel Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050503","article-title":"Single cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblasts in liver fibrosis","volume":"8","author":"Krenkel","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2023.03.038_bib111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.31743","article-title":"Heterogeneity of HSCs in a mouse model of NASH","volume":"74","author":"Rosenthal","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add3949","article-title":"An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib113","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.03.038_bib114","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib115","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib116","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/liv.15157","article-title":"Integrins as a drug target in liver fibrosis","volume":"42","author":"Rahman","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.03.038_bib117","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib118","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib119","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib120","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2017.01.021","article-title":"Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6","volume":"152","author":"Lai","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib121","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O'Farrell","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib122","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"Hernandez-Gea","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib123","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib124","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib126","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib127","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jhep.2011.07.010","article-title":"A\u00a0role for autophagy during hepatic stellate cell activation","volume":"55","author":"Thoen","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib128","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jhep.2020.04.044","article-title":"Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis","volume":"73","author":"Gao","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166235","article-title":"Nuclear receptors in liver fibrosis","volume":"1867","author":"Konigshofer","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2023.03.038_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010060","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2023.03.038_bib131","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.03.038_bib132","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.038_bib133","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fphar.2016.00033","article-title":"Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis","volume":"7","author":"Schon","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2023.03.038_bib134","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.2174\/1381612826666201023143542","article-title":"Role of microRNAs in hepatic stellate cells and hepatic fibrosis: an update","volume":"27","author":"Zhu","year":"2021","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhep.2023.03.038_bib135","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biomaterials.2019.03.025","article-title":"Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in\u00a0vivo","volume":"206","author":"Ergen","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jhep.2023.03.038_bib137","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42255-019-0076-1","article-title":"Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution","volume":"1","author":"Haas","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.03.038_bib138","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2015.03.039","article-title":"Mechanisms of liver fibrosis resolution","volume":"63","author":"Tacke","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib139","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.03.038_bib140","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1172\/JCI122258","article-title":"Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223","volume":"129","author":"Calvente","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.03.038_bib141","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1038\/s41467-021-24734-0","article-title":"CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells","volume":"12","author":"Koda","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2023.03.038_bib142","first-page":"10","article-title":"Cellular and molecular mechanisms underlying liver fibrosis regression","author":"Caligiuri","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2023.03.038_bib143","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.038_bib144","article-title":"The liver matrisome - looking beyond collagens","volume":"2","author":"Arteel","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.03.038_bib145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jhep.2020.09.014","article-title":"Cell therapy for advanced liver diseases: repair or rebuild","volume":"74","author":"Dwyer","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib147","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMcibr2201182","article-title":"Fighting cardiac fibrosis with CAR T cells","volume":"386","author":"Friedman","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib148","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in\u00a0vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jhep.2023.03.038_bib149","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.24315","article-title":"Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.038_bib150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2017.05.022","article-title":"Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by\u00a0modulating immune microenvironment in mice","volume":"67","author":"Ma","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib151","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.03.038_bib152","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-019-1802-2","article-title":"An acute immune response underlies the benefit of cardiac stem cell therapy","volume":"577","author":"Vagnozzi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2023.03.038_bib153","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jhep.2023.03.038_bib154","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41590-022-01146-w","article-title":"Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in\u00a0vivo","volume":"23","author":"Subramanian","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib155","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.32129","article-title":"Extracellular vesicles derived from mesenchymal stem\/stromal cells: the regenerative impact in liver diseases","volume":"75","author":"Psaraki","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2023.03.038_bib156","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.03.038_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126696","article-title":"Combined therapy with a CCR2\/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis","volume":"23","author":"Puengel","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.03.038_bib158","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2023.03.038_bib159","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jhep.2022.06.018","article-title":"Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH","volume":"77","author":"Naoumov","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823002180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823002180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:52:49Z","timestamp":1759175569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823002180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0168827823002180"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}